TABLE 2.
Summary of Case Reports Included for Review (n = 9)
| Article | SGLT2 Inhibitor | Sex | Age, years | A1C, % | Time to Development of FG | Concomitant Drugs |
|---|---|---|---|---|---|---|
| Kumar et al., 2017 (20) | Empagliflozin | M | 42 | 11.2 | 14 months | Metformin |
| Omer et al., 2018 (21) | Dapagliflozin | M | 60 | — | 5 months | Glicazide, metformin |
| Onder et al., 2019 (22) | Dapagliflozin | M | 64 | 7.4 | 6 months | Insulin, metformin, vildagliptin |
| Elshimy et al., 2019 (23) | Empagliflozin | M | 57 | — | 10 days | Glipizide, linagliptin, metformin |
| Nagano et al., 2019 (24) | Empagliflozin | M | 34 | 6.5 | 142 days | Glibenclamide, sitagliptin |
| Rodler et al., 2019 (25) | Dapagliflozin | M | 39 | — | 4 years | Amlodipine, levothyroxine, metformin, sitagliptin, valsartan |
| Elbeddini et al., 2020 (26) | Canagliflozin | M | 72 | 7.5 | 6 years | Glargine, metformin, sitagliptin |
| García-García et al., 2020 (27) | Dapagliflozin | M | 68 | 7.8 | 2–3 years | Glargine, metformin, sitagliptin |
| Kasbawala et al., 2020 (28) | Canagliflozin | F | 37 | 9.8 | 1 months | Cetirizine, citalopram, levothyroxine, lisinopril, metformin, pantoprazole, pravastatin, sitagliptin, trazodone, valacyclovir |
The diagnosis in all case reports was type 2 diabetes, and the outcome was hospitalization. F, female; M, male.